Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101619 | 0.90 | KMT2A (0.37) | POLBLMNAEPHX2NR1H4SMN1; SMN2 | |
| SCHEMBL22101957 | 0.87 | CA12 (0.31) | POLBLMNA | |
| SCHEMBL22101653 | 0.86 | MAPK14 (0.41) | MAPK14POLBPARP10MAOBMAPT | |
| SCHEMBL22101622 | 0.86 | LMNA (0.32) | POLBLMNASMN1; SMN2 | |
| SCHEMBL22101774 | 0.86 | LMNA (0.31) | POLBLMNA | |
| SCHEMBL22101977 | 0.86 | SMN1; SMN2 (0.40) | POLBLMNAEPHX2SMN1; SMN2MAOB | |
| SCHEMBL22101590 | 0.86 | LMNA (0.31) | POLBLMNASMN1; SMN2 | |
| SCHEMBL22101989 | 0.86 | ESR1 (0.31) | POLBLMNAMAPT | |
| SCHEMBL22101993 | 0.85 | ALDH1A1 (0.39) | POLBEPHX2NR1H4SMN1; SMN2KDM4E | |
| SCHEMBL22101958 | 0.85 | LMNA (0.30) | POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | MAPK14 4758/4885NOS1 3391/4885POLB 1445/4885 |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | MAPK14 4758/4885NOS1 3391/4885POLB 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.